AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a clinical-stage biotechnology company advancing oligonucleotide therapies with a focus on curing chronic hepatitis B (CHB) infection, appointed Will Wei head of chemistry, manufacturing and controls (CMC), senior vice president.

Wei brings over two decades of leadership in the biotech and pharmaceutical industry. He previously held key leadership roles at global pharmaceutical companies such as GSK as a director of CMC, and Roche as a senior director of CMC. Wei spearheaded teams responsible for process development, clinical supply chain management, and successful regulatory submissions for both China and Global markets.

“We are excited to welcome Dr. Wei to AusperBio’s leadership team at this pivotal time for the company,” said Guofeng Cheng, CEO. “Will’s depth and breadth of experience in end-to-end CMC operations, strategic insight will be instrumental in executing our plans, propelling our pipeline, and navigating the dynamic landscape of drug development.”

Wei said, “Joining AusperBio is both an honor and an exciting opportunity. I am inspired by AusperBio’s mission, and extremely impressed by the clinical data and the forging-ahead development speed of AHB-137 program. I’m excited to lead and collaborate with the outstanding team, building upon the company’s robust scientific foundation, to advance HBV cure and beyond and make a meaningful impact on patient care.”